Pyxis Oncology (PYXS) Competitors $1.16 -0.03 (-2.52%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.18 +0.02 (+1.72%) As of 07/11/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PYXS vs. CRVS, PVLA, TSVT, TNXP, ALLO, INZY, ALDX, CADL, ACB, and SGMTShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Corvus Pharmaceuticals (CRVS), Palvella Therapeutics (PVLA), 2seventy bio (TSVT), Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), Aurora Cannabis (ACB), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Its Competitors Corvus Pharmaceuticals Palvella Therapeutics 2seventy bio Tonix Pharmaceuticals Allogene Therapeutics Inozyme Pharma Aldeyra Therapeutics Candel Therapeutics Aurora Cannabis Sagimet Biosciences Corvus Pharmaceuticals (NASDAQ:CRVS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Which has more risk and volatility, CRVS or PYXS? Corvus Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Is CRVS or PYXS more profitable? Corvus Pharmaceuticals' return on equity of -24.04% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -24.04% -13.90% Pyxis Oncology N/A -57.49%-45.17% Do analysts prefer CRVS or PYXS? Corvus Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 262.32%. Pyxis Oncology has a consensus price target of $9.00, suggesting a potential upside of 675.86%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable earnings and valuation, CRVS or PYXS? Corvus Pharmaceuticals has higher earnings, but lower revenue than Pyxis Oncology. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.22Pyxis Oncology$16.15M4.45-$77.33M-$1.59-0.73 Do insiders and institutionals hold more shares of CRVS or PYXS? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CRVS or PYXS? In the previous week, Pyxis Oncology had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Pyxis Oncology and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Pyxis Oncology's score of 0.99 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Corvus Pharmaceuticals Very Positive Pyxis Oncology Positive SummaryCorvus Pharmaceuticals beats Pyxis Oncology on 8 of the 12 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.86M$2.41B$5.55B$9.08BDividend YieldN/A1.79%5.25%4.02%P/E RatioN/A9.4228.2620.26Price / Sales4.45595.94411.94152.32Price / CashN/A164.4637.1257.67Price / Book0.574.608.045.49Net Income-$77.33M$31.26M$3.19B$250.45M7 Day Performance4.04%4.80%3.62%4.79%1 Month Performance-3.33%8.17%5.98%9.59%1 Year Performance-63.17%-3.88%29.39%16.41% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology2.3034 of 5 stars$1.16-2.5%$9.00+675.9%-63.2%$71.86M$16.15M0.0060CRVSCorvus Pharmaceuticals2.864 of 5 stars$3.90-1.3%$15.00+284.6%+102.0%$269.27MN/A-3.9830Positive NewsPVLAPalvella Therapeutics2.5038 of 5 stars$24.90+3.2%$46.29+85.9%N/A$266.66M$42.81M-2.06N/ATSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440TNXPTonix Pharmaceuticals2.6696 of 5 stars$35.44-0.1%$585.00+1,550.7%-32.0%$261.03M$10.09M-0.0250Trending NewsALLOAllogene Therapeutics3.6025 of 5 stars$1.16-2.5%$8.44+628.0%-53.6%$260.29M$20K-0.94310News CoveragePositive NewsGap UpINZYInozyme Pharma3.2578 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750ALDXAldeyra Therapeutics2.6043 of 5 stars$4.35+1.2%$9.50+118.4%+20.5%$257.55MN/A-4.4810Positive NewsCADLCandel Therapeutics2.497 of 5 stars$4.99-2.2%$22.00+340.9%-4.8%$255.53MN/A-3.7260Positive NewsAnalyst UpgradeAnalyst RevisionACBAurora Cannabis0.3046 of 5 stars$4.43-2.4%N/A-25.3%$255.21M$246.72M40.271,130SGMTSagimet Biosciences2.8344 of 5 stars$8.68+5.2%$26.60+206.5%+184.4%$253.07M$2M-4.938Positive News Related Companies and Tools Related Companies CRVS Alternatives PVLA Alternatives TSVT Alternatives TNXP Alternatives ALLO Alternatives INZY Alternatives ALDX Alternatives CADL Alternatives ACB Alternatives SGMT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PYXS) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
